Serina Therapeutics (SER) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 10, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	1-38519
Entity Registrant Name	AgeX Therapeutics, Inc.
Entity Central Index Key	0001708599
Entity Tax Identification Number	82-1436829
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1101 Marina Village Parkway
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	Alameda
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94501
City Area Code	510
Local Phone Number	671-8370
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	AGE
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		37,939,176

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021		Dec. 31, 2020
CURRENT ASSETS
Cash and cash equivalents	$ 731		$ 527
Accounts and grants receivable, net	24		326
Prepaid expenses and other current assets	720		1,430
Total current assets	1,475		2,283
Deposits and other long-term assets	50		50
Intangible assets, net	902		1,592
TOTAL ASSETS	2,427		3,925
CURRENT LIABILITIES
Accounts payable and accrued liabilities	924	[1]	1,656
Loan due to Juvenescence, net of debt issuance cost, current portion	5,600		1,960
Related party payables, net	71		71
Deferred revenues, current portion			275
Paycheck Protection Program Loan			436
Insurance premium liability and other current liabilities	3		959
Total current liabilities	6,598		5,357
Loan due to Juvenescence, net of debt issuance cost, net of current portion	5,807		3,900
Deferred revenues, net of current portion			64
TOTAL LIABILITIES	12,405		9,321
Commitments and contingencies (Note 10)
STOCKHOLDERS’ DEFICIT
Preferred stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding as of September 30, 2021 and December 31, 2020
Common stock, $0.0001 par value, 100,000 shares authorized; and 37,939 and 37,691 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	4		4
Additional paid-in capital	93,650		91,810
Accumulated other comprehensive income			143
Accumulated deficit	(103,590)		(97,073)
AgeX Therapeutics, Inc. stockholders’ deficit	(9,936)		(5,116)
Noncontrolling interest	(42)		(280)
Total stockholders’ deficit	(9,978)		(5,396)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 2,427		$ 3,925
[1]	Reflects the effect of the LifeMap Deconsolidation. See Note 3.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	37,939,176	37,691,047
Common stock, shares outstanding	37,939,176	37,691,047

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
REVENUES:
Total revenues	$ 24,000	$ 69,000	$ 117,000	$ 203,000
Cost of sales	(2,000)	(17,000)	(18,000)	(21,000)
Gross profit	22,000	52,000	99,000	182,000
Research and development	275,000	653,000	1,080,000	2,809,000
General and administrative	1,421,000	1,796,000	5,191,000	5,146,000
Total operating expenses	1,696,000	2,449,000	6,271,000	7,955,000
Gain on deconsolidation of LifeMap Sciences (Note 3)			106,000
Loss from operations	(1,674,000)	(2,397,000)	(6,066,000)	(7,773,000)
OTHER EXPENSE, NET:
Interest expense, net	(285,000)	(127,000)	(802,000)	(222,000)
Other income, net	4,000		445,000	6,000
Total other expense, net	(281,000)	(127,000)	(357,000)	(216,000)
NET LOSS FROM CONTINUING OPERATIONS	(1,955,000)	(2,524,000)	(6,423,000)	(7,989,000)
NET LOSS FROM DISCONTINUED OPERATIONS (Note 3)		(41,000)	(103,000)	(529,000)
NET LOSS	(1,955,000)	(2,565,000)	(6,526,000)	(8,518,000)
Net loss attributable to noncontrolling interest from continuing operations		2,000	2,000	3,000
Net loss attributable to noncontrolling interest from discontinued operations		20,000	7,000	96,000
NET LOSS ATTRIBUTABLE TO AGEX	$ (1,955,000)	$ (2,543,000)	$ (6,517,000)	$ (8,419,000)
NET LOSS PER COMMON SHARE:
Continuing operations	$ (0.05)	$ (0.07)	$ (0.17)	$ (0.21)
Discontinued operations				(0.01)
BASIC AND DILUTED	$ (0.05)	$ (0.07)	$ (0.17)	$ (0.22)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:
BASIC AND DILUTED	37,938	37,679	37,868	37,662
AMOUNTS ATTRIBUTABLE TO AGEX:
Loss from continuing operations	$ (1,955,000)	$ (2,522,000)	$ (6,421,000)	$ (7,986,000)
Loss from discontinued operations		(21,000)	(96,000)	(433,000)
Grant Revenues [Member]
REVENUES:
Total revenues	22,000	40,000	79,000	162,000
Other Revenues [Member]
REVENUES:
Total revenues	$ 2,000	$ 29,000	$ 38,000	$ 41,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
NET LOSS	$ (1,955,000)	$ (2,565,000)	$ (6,526,000)	$ (8,518,000)
Other comprehensive income (expense), net of tax:
Foreign currency translation adjustments from discontinued operations		11,000	(143,000)	23,000
COMPREHENSIVE LOSS	(1,955,000)	(2,554,000)	(6,669,000)	(8,495,000)
Less: Comprehensive loss attributable to noncontrolling interest from continuing operations		2,000	2,000	3,000
Less: Comprehensive loss attributable to noncontrolling interest from discontinued operations		20,000	7,000	96,000
COMPREHENSIVE LOSS ATTRIBUTABLE TO AGEX COMMON STOCKHOLDERS	(1,955,000)	(2,532,000)	(6,660,000)	(8,396,000)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to AgeX			(6,421,000)	(7,986,000)
Net loss attributable to noncontrolling interest			(2,000)	(3,000)
Adjustments to reconcile net loss attributable to AgeX to net cash used in operating activities:
Gain on deconsolidation of LifeMap Sciences (Note 3)			(106,000)
Gain on extinguishment of debt (Paycheck Protection Program Loan)			(437,000)
Depreciation expense				370,000
Amortization of intangible assets		33,000	98,000	98,000
Amortization of right-of-use asset				316,000
Amortization of debt issuance cost			820,000	277,000
Stock-based compensation	272,000	227,000	736,000	732,000
Changes in operating assets and liabilities:
Accounts and grants receivable, net			129,000	52,000
Prepaid expenses and other current assets			682,000	652,000
Accounts payable and accrued liabilities			(619,000)	229,000
Related party payables				16,000
Insurance premium liability			(921,000)	(713,000)
Other current liabilities			(77,000)	(429,000)
Net cash used in operating activities from continuing operations			(6,118,000)	(6,389,000)
Net cash provided by (used in) operating activities from discontinued operations (Note 3)			(90,000)	192,000
Net cash used in operating activities			(6,208,000)	(6,197,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of LifeMap Sciences (Note 3)			466,000
Purchase of equipment and other				(20,000)
Net cash provided by (used in) investing activities from continuing operations			466,000	(20,000)
Deconsolidation of cash and cash equivalents from discontinued operations (Note 3)			(50,000)
Net cash provided by (used in) investing activities			416,000	(20,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Draw down on loan facility from Juvenescence			5,500,000	4,700,000
Proceeds from the issuance of common stock			496,000
Partial collection on loan due from LifeMap Sciences			250,000
Proceeds from Paycheck Protection Program Loan				433,000
Payment of debt related costs				(149,000)
Repayment of financing lease liability				(15,000)
Net cash provided by financing activities from continuing operations			6,246,000	4,969,000
Partial payment on loan due to AgeX from discontinued operations (Note 3)			(250,000)
Net cash provided by financing activities			5,996,000	4,969,000
Effect of exchange rate changes on cash, cash equivalents and restricted cash				3,000
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH			204,000	(1,245,000)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:
At beginning of the period			577,000	2,452,000
At end of the period	$ 781,000	$ 1,207,000	$ 781,000	$ 1,207,000

Organization, Business Overview

Organization, Business Overview and Liquidity	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Business Overview and Liquidity	1. Organization, Business Overview and Liquidity AgeX Therapeutics, Inc. (“AgeX”) was incorporated in January 2017 in the state of Delaware as a subsidiary of Lineage Cell Therapeutics, Inc. (“Lineage,” formerly known as BioTime, Inc.), a publicly traded, clinical-stage biotechnology company. AgeX is a biotechnology company focused on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. AgeX’s mission is to apply its comprehensive experience in fundamental biological processes of human aging to a broad range of age-associated medical conditions. AgeX’s proprietary technology, based on telomerase-mediated cellular immortality and regenerative biology, allows AgeX to utilize telomerase-expressing regenerative pluripotent stem cells (“PSCs”) for the manufacture of cell-based therapies to regenerate tissues afflicted with age-related chronic degenerative disease. AgeX’s main technology platforms and product candidates are: ● PureStem ® ● UniverCyte™ which uses the HLA-G gene to suppress rejection of transplanted cells and tissues to confer low immune observability to cells; ● AGEX-BAT1 using adipose brown fat cells for metabolic diseases such as Type II diabetes; ● AGEX-VASC1 using vascular progenitor cells to treat tissue ischemia; and ● Induced tissue regeneration or iTR technology to regenerate or rejuvenate cells to treat a variety of degenerative diseases including those associated with aging, as well as other potential tissue regeneration applications such as scarless wound repair. Emerging Growth Company AgeX is an “emerging growth company” as defined in the Jumpstart our Business Startups Act of 2012. Disposition and Deconsolidation of LifeMap Sciences As discussed in Note 3, on March 6, 2021, AgeX and its then majority-owned subsidiary LifeMap Sciences, Inc. (“LifeMap Sciences”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Atlas Capital Partners Limited, a British Virgin Islands company limited by shares (“Atlas”), and GCLMS Acquisition Corporation (“GCLMS”), a Delaware corporation that was a wholly-owned subsidiary of Atlas. On March 15, 2021, the merger was completed pursuant to the terms of the Merger Agreement. As a result of the merger, GCLMS merged into LifeMap Sciences and (a) the shares of LifeMap Sciences common stock outstanding at the time of the merger entitled the holders of those shares to receive a pro rata portion of a $ 500,000 AgeX received approximately $ 466,400 1,761,296 250,000 As a result of the completion of the cash-out merger on March 15, 2021, LifeMap Sciences is no longer a subsidiary of AgeX. Accordingly, AgeX has deconsolidated LifeMap Sciences’ consolidated financial statements and consolidated results of operations from AgeX, effective March 15, 2021 (the “LifeMap Deconsolidation”), in accordance with Accounting Standards Codification, or ASC 810-10-40, Consolidation Going Concern AgeX primarily finances its operations through sales of its common stock, loans from its largest stockholder Juvenescence Limited (“Juvenescence”), and research grants. AgeX has incurred operating losses and negative cash flows since inception and had an accumulated deficit of $ 103.6 Based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets, AgeX’s board of directors and management have adopted operating plans and budgets to extend the period over which AgeX can continue its operations with its available cash resources. Notwithstanding those operating plans and budgets, based on AgeX’s most recent projected cash flows AgeX believes that its cash and cash equivalents of $ 0.7 million as of September 30, 2021 plus the loan facilities provided by Juvenescence to advance up to an additional $ 1.0 million to AgeX as of September 30, 2021 plus another $ 1.0 Staff Reductions and Elimination of Laboratory Facilities Lease During April 2020, AgeX initiated staff layoffs that affected 11 105,000 195,000 Following the staff reductions, AgeX subleased out a significant portion of its leased laboratory space and did not renew its lease or enter into a new lease for a replacement facility when its lease expired on December 31, 2020. Instead, AgeX entered into a lease for a smaller office only space commencing January 1, 2021. Liquidity and Impact of COVID-19 In addition to general economic and capital market trends and conditions, AgeX’s ability to raise sufficient additional capital to finance its operations from time to time will depend on a number of factors specific to AgeX’s operations such as operating expenses and progress in out-licensing its technologies and development of its product candidates. The availability of financing may be adversely impacted by the COVID-19 pandemic which could depress national and international economies and disrupt capital markets, supply chains, and aspects of AgeX’s operations. The extent to which the ongoing COVID-19 pandemic will ultimately impact AgeX’s business, results of operations, financial condition, or cash flows is highly uncertain and difficult to predict because it will depend on many factors that are outside AgeX’s control. The unavailability or inadequacy of financing to meet future capital needs could force AgeX to modify, curtail, delay, or suspend some or all aspects of planned operations. Sales of additional equity securities could result in the dilution of the interests of its shareholders. AgeX cannot assure that adequate financing will be available on favorable terms, if at all.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	2. Basis of Presentation and Summary of Significant Accounting Policies The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with generally accepted accounting principles in the United States of America (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2020 was derived from the audited consolidated financial statements at that date but does not include all the information and footnotes required by GAAP. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2020. The accompanying condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of AgeX’s financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Principles of consolidation AgeX’s condensed consolidated interim financial statements include the accounts of its subsidiaries and certain research and development departments. AgeX consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because AgeX has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of stockholders’ deficit on AgeX’s condensed consolidated balance sheets. AgeX’s consolidated balance sheet at December 31, 2020, as reported, includes LifeMap Sciences’ consolidated assets and liabilities, after intercompany eliminations. However, LifeMap Sciences’ consolidated assets and liabilities are not included in AgeX’s unaudited condensed consolidated balance sheet at September 30, 2021, due to the deconsolidation of LifeMap Sciences on March 15, 2021. LifeMap Sciences’ consolidated financial statements and consolidated results of operations include its wholly-owned and consolidated subsidiary LifeMap Sciences, Ltd. AgeX’s unaudited condensed consolidated statements of operations for the nine months ended September 30, 2021 include LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the deconsolidation due to the conversion of $ 1,761,296 AgeX has one operating subsidiary, ReCyte Therapeutics, Inc. (“ReCyte”). ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns 94.8 Revenue recognition During the first quarter of 2018, AgeX adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASU 2014-09, Revenues from Contracts with Customers (Topic 606) AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. Subscription and advertisement revenues ® ® LifeMap Sciences licensed from third parties the databases and software it commercialized and had a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in operating loss from discontinued operations on the condensed consolidated statements of operations when the cash was received and the royalty obligation was incurred as the royalty payments did not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs - Contracts with Customers For the three and nine months ended September 30, 2020, LifeMap Sciences recognized $ 309,000 945,000 267,000 No Grant revenues – AgeX believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC 606. In September 2018, AgeX was awarded a grant of up to approximately $ 225,000 nil 25,000 On April 8, 2020, AgeX was awarded a grant of up to approximately $ 386,000 22,000 40,000 79,000 137,000 Arrangements with multiple performance obligations – Research and development Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies, including service revenues from co-development projects with customers, if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations. General and administrative General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees. Basic and diluted net loss per share attributable to common stockholders Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any. For the three and nine months ended September 30, 2021 and 2020, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive. The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (unaudited and in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Stock options 3,381 2,892 3,066 2,882 Warrants (1) 3,512 2,036 3,485 1,029 Restricted stock units 21 34 24 39 (1) As of September 30, 2021 and 2020, AgeX had issued Juvenescence warrants to purchase 3,512,098 2,638,401 Leases On January 1, 2019, AgeX adopted ASU 2016-02, Leases Codification Improvements to Topic 842, Leases Leases (Topic 842): Targeted Improvements AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Upon adoption of ASC 842 and based on the practical expedients available under that standard, AgeX did not reassess any expired or existing contracts, reassess the lease classification for any expired or existing leases and reassess initial direct costs for exiting leases. AgeX also elected not to capitalize leases that have terms of twelve months or less. AgeX’s sublease of its office and laboratory facility, which commenced on April 2, 2019 and ended on December 31, 2020, was subject to ASC 842. AgeX recognized its lease as a right-of-use asset included in property and equipment, net and operating lease liability on its balance sheet in accordance with ASC 842 up until the lease terminated on December 31, 2020 (see Note 10). During 2020, AgeX as a sublessor subleased portions of its office and laboratory space to certain unaffiliated third parties. These subleases are not accounted for under ASC 842 as amounts are not material and or the sublease periods are under one year. On November 3, 2020, AgeX entered into a one year lease effective January 1, 2021 for office space only comprising 135 square feet in a building in an office and research park at 1101 Marina Village Parkway, Suite 201, Alameda, California. Base monthly rent is $947 over the lease term. AgeX has elected to not apply the recognition requirements under ASC 842 and instead recognizes the lease payments as lease cost on a straight-line basis over the lease term as lease payments are not deemed material. AgeX has renewed this lease for another 12 months effective January 1, 2022 for base monthly rent of $1,074. AgeX has elected to not apply the recognition requirements under ASC 842 for the renewed lease agreement under the guidance for similar reasons aforementioned. Restricted Cash In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash Schedule of Cash, Cash Equivalents and Restricted Cash 2021 2020 2020 2019 September 30, December 31, September 30, December 31, 2021 2020 2020 2019 (unaudited) (unaudited) Cash and cash equivalents $ 731 $ 527 $ 1,107 $ 2,352 Restricted cash included in deposits and other long-term assets 50 50 100 100 Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows $ 781 $ 577 $ 1,207 $ 2,452 Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. All restricted cash was included in deposits and other long-term assets in the condensed consolidated balance sheets. Reclassifications Certain reclassifications have been made to the prior years’ consolidated financial statements to conform to current year presentation of discontinued operations. Certain financial information is presented on a rounded basis, which may cause minor differences. See Note 3 for further information on discontinued operations. Recently adopted accounting pronouncement In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40) Recently issued accounting pronouncements not yet adopted The recently issued accounting pronouncements applicable to AgeX that are not yet effective should be read in conjunction with the recently issued accounting pronouncements, as applicable and disclosed in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2020. In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) CARES Act On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. AgeX reviewed the provisions of the CARES Act but does not expect it to have a material impact to its tax provision or its condensed consolidated financial statements. As described in Note 10, AgeX has obtained a loan under the Paycheck Protection Program under the CARES Act, the repayment of which was forgiven in February 2021.

Disposition and Deconsolidation

Disposition and Deconsolidation of LifeMap Sciences	9 Months Ended
	Sep. 30, 2021
Insurance [Abstract]
Disposition and Deconsolidation of LifeMap Sciences	3. Disposition and Deconsolidation of LifeMap Sciences Discontinued Operations On March 6, 2021, AgeX and LifeMap Sciences entered into the Merger Agreement with Atlas and GCLMS. On March 15, 2021, the merger was completed pursuant to the terms of the Merger Agreement. As a result of the merger, GCLMS merged into LifeMap Sciences and (a) the shares of LifeMap Sciences common stock outstanding at the time of the merger entitled the holders of those shares to receive a pro rata portion of the $ 500,000 AgeX received approximately $ 466,400 1,761,296 250,000 The following table presents the major classes of assets and liabilities of LifeMap Sciences included in AgeX’s condensed consolidated balance sheet as of December 31, 2020 (in thousands). Schedule of Discontinued Operations December 31, 2020 Cash and cash equivalents $ 391 Accounts and grants receivable, net 173 Prepaid expenses and other current assets 7 Total current assets 571 Intangible assets, net 591 Accounts payable and accrued liabilities 161 Deferred revenues 275 Insurance premium and other current liabilities 1,995 Total current liabilities 2,431 Deferred revenues, net of current portion 64 Net liabilities of discontinued operations $ (1,333 ) The results of operations and cash flows for LifeMap Sciences are reported as discontinued operations under GAAP in accordance with ASC 205-20, Discontinued Operations 2021 2020 2021 2020 Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net revenues $ - $ 365 $ 277 $ 1,160 Costs, operating and other expenses - (406 ) (380 ) (1,689 ) Loss from discontinued operations - (41 ) (103 ) (529 ) Net loss from discontinued operations attributable to noncontrolling interest - 20 7 96 Loss from discontinued operations (1) $ - $ (21 ) $ (96 ) $ (433 ) (1) Does not include $ 106,000 Gain on deconsolidation of LifeMap Sciences Deconsolidation As a result of the completion of the cash-out merger on March 15, 2021, LifeMap Sciences is no longer a subsidiary of AgeX. Effective March 15, 2021, AgeX deconsolidated LifeMap Sciences’ consolidated financial statements and consolidated results of operations from those of AgeX under US generally accepted accounting principles ASC 810-10-40-4, Deconsolidation of a Subsidiary or Derecognition of a Group of Assets AgeX’s consolidated balance sheet at December 31, 2020, as reported, includes LifeMap Sciences’ consolidated assets and liabilities, after intercompany eliminations. However, LifeMap Sciences’ consolidated assets and liabilities are not included in AgeX’s unaudited condensed consolidated balance sheet at September 30, 2021 due to the LifeMap Deconsolidation on March 15, 2021. AgeX’s unaudited condensed consolidated statements of operations for the nine months ended September 30, 2021 include LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the LifeMap Deconsolidation due to the conversion of $ 1,761,296 AgeX recognized a gain of $ 106,000

Selected Balance Sheet Componen

Selected Balance Sheet Components	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Selected Balance Sheet Components	4. Selected Balance Sheet Components Property and equipment, net At September 30, 2021 and December 31, 2020, property and equipment in the amount of $ 381,000 230,000 686,000 Intangible assets, net At September 30, 2021 and December 31, 2020, intangible assets, primarily consisting of acquired in-process research and development and patents, and accumulated amortization were as follows (in thousands): Schedule of Intangible Assets, Net September 30, 2021 (unaudited) (1) December 31, 2020 Intangible assets $ 1,312 $ 5,586 Accumulated amortization (410 ) (3,994 ) Total intangible assets, net $ 902 $ 1,592 (1) Reflects the effect of the LifeMap Deconsolidation. See Note 3. AgeX recognized $ 32,000 98,000 33,000 98,000 Amortization expense of intangible assets for discontinued operations for the nine months September 30, 2021 amounted to $ 89,000 107,000 321,000 Accounts payable and accrued liabilities At September 30, 2021 and December 31, 2020, accounts payable and accrued liabilities were comprised of the following (in thousands): Schedule of Accounts Payable and Accrued Liabilities September 30, 2021 (unaudited) (1) December 31, 2020 Accounts payable $ 184 (1) $ 761 Accrued compensation 201 (1) 228 Accrued vendors and other expenses 539 (1) 667 Total accounts payable and accrued liabilities $ 924 (1) $ 1,656 (1) Reflects the effect of the LifeMap Deconsolidation. See Note 3.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	5. Related Party Transactions Transactions with Juvenescence 2019 Loan Agreement On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence has provided to AgeX a $ 2.0 18 4.0 2.0 5.5 6.0 In lieu of accrued interest, AgeX issued to Juvenescence 19,000 56,000 10 In lieu of repayment of funds borrowed, AgeX or Juvenescence may convert the loan balance (including principal and accrued interest, if any) into AgeX common stock or “units” if AgeX consummates a “Qualified Offering” which means a sale of common stock (or common stock paired with warrants or other convertible securities in “units”) in which the gross sale proceeds are at least $ 7.5 Events of Default under the 2019 Loan Agreement include: (i) AgeX fails to pay any amount in the manner and at the time provided in the 2019 Loan Agreement and the failure to pay is not remedied within 10 business days; (ii) AgeX fails to perform any of its obligations under the 2019 Loan Agreement and if the failure can be remedied it is not remedied to the satisfaction of Juvenescence within 10 business days after notice to AgeX; (iii) other indebtedness for money borrowed in excess of $ 100,000 25,000 As consideration for the line of credit under the 2019 Loan Agreement, AgeX issued to Juvenescence warrants to purchase 150,000 2.60 236,000 The Amendment also grants Juvenescence the right to convert the principal amount of outstanding loans under the 2019 Loan Agreement, as amended, into shares of AgeX common stock at the Market Price as defined in the Amendment. The Amendment places certain limits on the number of shares that may be issued upon conversion of outstanding loan amounts by Juvenescence, or by AgeX under AgeX’s loan conversion rights, if under the rules of the NYSE American or any other national securities exchange on which AgeX common stock may be listed, approval by AgeX stockholders would be required in connection with the issuance of the shares. Under those limits (a) the number of shares of common stock that may be issued upon conversion of any loan advance, at a conversion price that is lower than the market price of AgeX common stock at the time of funding the applicable advance being converted, may not exceed 19.9% of the shares outstanding at August 13, 2019, and (b) no advances may be converted into common stock in an amount that would cause Juvenescence’s ownership of AgeX common stock to equal or exceed 50% of the number of shares of AgeX common stock then outstanding. AgeX will pay Juvenescence an Origination Fee in the amount of $ 160,000 2020 Loan Agreement On March 30, 2020, AgeX and Juvenescence entered into a new Secured Convertible Facility Agreement (the “2020 Loan Agreement”) pursuant to which Juvenescence has agreed to provide to AgeX an $ 8.0 18 500,000 1 28,500 3 March 30, 2023 On July 21, 2020, AgeX and Juvenescence entered into an amendment to the 2020 Loan Agreement that waived (i) certain provisions requiring that, as a condition to the funding of a third draw of funds, AgeX and the Guarantor Subsidiaries execute a Security Agreement and related documents pledging certain assets as collateral, and (ii) certain provisions providing that the Guarantor Subsidiaries would guarantee AgeX’s obligations under the 2020 Loan Agreement, in each case subject to an acknowledgement by AgeX and the Guarantor Subsidiaries that Juvenescence may, in its discretion, condition any advances under the 2020 Loan Agreement subsequent to the third draw of funds on the receipt of such collateral agreements and guarantees. Through September 30, 2021, AgeX had drawn a total of $ 7.5 million against the $ 8.0 million line of credit. AgeX may draw additional funds from time to time subject to Juvenescence’s discretion, prior to the Repayment Date on March 30, 2023. AgeX may not draw down funds if an “Event of Default” under the 2020 Loan Agreement has occurred and is continuing. The outstanding principal balance of the loans under the 2020 Loan Agreement will become due and payable on the Repayment Date. Under the terms of the 2020 Loan Agreement, each time AgeX received an advance of funds under the 2020 Loan Agreement, AgeX issued to Juvenescence a number of New Warrants equal to 50% of the number determined by dividing the amount of the advance by the applicable Market Price. The Market Price set each New Warrant when issued was the closing price per share of AgeX common stock on the NYSE American on the date of the applicable notice from AgeX requesting a draw of funds that triggered the obligation to issue the New Warrant. The exercise price of the New Warrants is the applicable Market Price. The New Warrants will expire at 5:00 p.m. New York time three years after the date of issue. As of September 30, 2021 AgeX had issued to Juvenescence New Warrants to purchase 3,362,098 0.70 1.895 Registration Rights AgeX entered into certain Registration Rights Agreements pursuant to which it has agreed to register for sale under the Securities Act of 1933, as amended (the “Securities Act”) all shares of AgeX common stock presently held by Juvenescence or that may be acquired by Juvenescence through the exercise of common stock purchase warrants that they hold or that they may acquire pursuant to the 2020 Loan Agreement, and shares that they may acquire through the conversion of loans under the 2019 Loan Agreement and the 2020 Loan Agreement, including principal and accrued interest, and the amount of the loan Origination Fee under the 2019 Loan Agreement, as amended. AgeX has filed a registration statement on Form S-3, which has become effective under the Securities Act, for offerings on a delayed or continuous basis covering 16,447,500 3,248,246 Related party payables Since October 2018, AgeX’s Chief Operating Officer (“COO”), who is also an employee of Juvenescence, is devoting a majority of his time to AgeX’s operations. AgeX reimburses Juvenescence for his services on an agreed-upon fixed annual amount of approximately $ 280,000 71,000

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders’ Equity (Deficit)	6. Stockholders’ Equity (Deficit) Preferred Stock AgeX is authorized to issue up to 5,000,000 0.0001 no Common Stock AgeX has 100,000,000 0.0001 37,939,176 37,691,047 Issuance and Sale of Warrants by AgeX Through September 30, 2021, as consideration for $ 7.5 3,362,098 28,500 On August 13, 2019, in lieu of accrued interest under the 2019 Loan Agreement, AgeX issued to Juvenescence 19,000 150,000 At-the-Market Offering Facility On January 8, 2021, AgeX entered into a sales agreement with Chardan Capital Markets LLC (“Chardan”), relating to the sale of shares of AgeX common stock, par value $ 0.0001 12.6 496,000 Reconciliation of Changes in Stockholders’ Equity (Deficit) The following tables provide the activity in stockholders’ equity (deficit) for the three and nine months ended September 30, 2021 and 2020 (unaudited and in thousands): Summary of Reconciliation Changes in Stockholders’ Equity Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income Equity (Deficit) Common Stock Additional Accumulated Other Total Stockholders’ Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income Equity (Deficit) BALANCE AT JUNE 30, 2021 37,937 $ 4 $ 93,379 $ (101,635 ) $ (42 ) $ - $ (8,294 ) Issuance of common stock Issuance of common stock, shares Issuance of warrants Transactions with noncontrolling interests – LifeMap Sciences Deconsolidation of LifeMap Sciences Foreign currency translation adjustment Issuance of common stock to Juvenescence Issuance of common stock to juvenescence , shares Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 2 - (1 ) - - - (1 ) Stock-based compensation - - 272 - - - 272 Net loss - - - (1,955 ) - - (1,955 ) BALANCE AT SEPTEMBER 30, 2021 37,939 $ 4 $ 93,650 $ (103,590 ) $ (42 ) $ - $ (9,978 ) Common Stock Additional Accumulated Other Total Stockholders’ Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income Equity (Deficit) BALANCE AT DECEMBER 31, 2020 37,691 $ 4 $ 91,810 $ (97,073 ) $ (280 ) $ 143 $ (5,396 ) Issuance of common stock 242 - 475 - - - 475 Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 6 - (6 ) - - - (6 ) Issuance of warrants - - 757 - - - 757 Stock-based compensation - - 740 - - - 740 Transactions with noncontrolling interests – LifeMap Sciences - - (269 ) - 269 - - Deconsolidation of LifeMap Sciences - - 143 - (22 ) (143 ) (22 ) Net loss - - - (6,517 ) (9 ) - (6,526 ) BALANCE AT SEPTEMBER 30, 2021 37,939 $ 4 $ 93,650 $ (103,590 ) $ (42 ) $ - $ (9,978 ) Common Stock Additional Accumulated Other Total Stockholders’ Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income Equity (Deficit) BALANCE AT JUNE 30, 2020 37,658 $ 4 $ 89,555 $ (92,084 ) $ 322 $ 81 $ (2,122 ) Issuance of common stock to Juvenescence 29 - 37 - - - 37 Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 2 - (1 ) - - - (1 ) Issuance of warrants to Juvenescence - - 662 - - - 662 Stock-based compensation - - 232 - - - 232 Transactions with noncontrolling interests – LifeMap Sciences - - 395 - (395 ) - - Foreign currency translation adjustment - - - - - 11 11 Net loss - - - (2,543 ) (22 ) - (2,565 ) BALANCE AT SEPTEMBER 30, 2020 37,689 $ 4 $ 90,880 $ (94,627 ) $ (95 ) $ 92 $ (3,746 ) Common Stock Additional Accumulated Other Total Stockholders’ Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income Equity (Deficit) BALANCE AT DECEMBER 31, 2019 37,649 $ 4 $ 88,353 $ (86,208 ) $ 399 $ 69 $ 2,617 Balance 37,649 $ 4 $ 88,353 $ (86,208 ) $ 399 $ 69 $ 2,617 Issuance of common stock to Juvenescence 29 - 37 - - - 37 Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 11 - (7 ) - - - (7 ) Issuance of warrants to Juvenescence - - 1,351 - - - 1,351 Stock-based compensation - - 751 - - - 751 Transactions with noncontrolling interests – LifeMap Sciences - - 395 - (395 ) - - Foreign currency translation adjustment - - - - - 23 23 Net loss - - - (8,419 ) (99 ) - (8,518 ) BALANCE AT SEPTEMBER 30, 2020 37,689 $ 4 $ 90,880 $ (94,627 ) $ (95 ) $ 92 $ (3,746 ) Balance 37,689 $ 4 $ 90,880 $ (94,627 ) $ (95 ) $ 92 $ (3,746 )

Stock-Based Awards

Stock-Based Awards	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Stock-Based Awards	7. Stock-Based Awards Equity Incentive Plan Awards AgeX has an Equity Incentive Plan (the “Plan”) under which a maximum of 4,000,000 A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price): Summary of Stock Option Activity Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price December 31, 2020 1,046 2,854 28 $ 2.51 Options granted (568 ) 568 - 1.46 Options forfeited, cancelled or expired 40 (40 ) - 3.00 Restricted stock units vested - - (9 ) - September 30, 2021 518 3,382 19 $ 2.31 Options exercisable at September 30, 2021 2,398 $ 2.50 There have been no Stock-based Compensation Expense The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions including expected life, risk-free interest rates, volatility, and dividend yield. No stock options were granted under the Plan during the three months ended September 30, 2021 and 2020. Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options Nine Months Ended September 30, 2021 2020 Expected life (in years) 5.71 6.08 Risk-free interest rates 0.99 % 0.45 % Volatility 102.34 % 87.86 % Dividend yield - % - % Operating expenses include stock-based compensation expense as follows (unaudited and in thousands): Schedule of Stock Based Compensation Expense Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 17 $ 16 $ 48 $ 63 General and administrative 255 211 688 669 Total stock-based compensation expense – continued operations $ 272 $ 227 $ 736 $ 732 Stock-based compensation expense recognized under discontinued operations for the nine months ended September 30, 2021 amounted to $ 4,000 5,000 19,000

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes The provision for income taxes for interim periods is determined using an estimated annual effective tax rate in accordance with ASC 740-270, Income Taxes, Interim Reporting. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where AgeX conducts business. Beginning in 2018, the 2017 Tax Cuts and Jobs Act (“2017 Tax Act”) subjects a U.S. stockholder to tax on Global Intangible Low Tax Income “GILTI” earned by certain foreign subsidiaries. In general, GILTI is the excess of a U.S. shareholder’s total net foreign income over a deemed return on tangible assets. The provision further allows a deduction of 50 For the three and nine months ended September 30, 2021, AgeX experienced a domestic loss from continuing operations and a foreign loss; therefore, no The sale of LifeMap Sciences was a taxable transaction to AgeX, however no income tax is due as the transaction resulted in a taxable loss primarily due to AgeX’s tax basis in the subsidiary. Due to losses incurred for all periods presented, AgeX did not record a domestic provision or benefit for income taxes. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. AgeX established a full valuation allowance for all of its domestic deferred tax assets for all periods presented due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	9. Supplemental Cash Flow Information Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 are as follows (unaudited and in thousands): Schedule Non-cash Investing and Financing Transactions 2021 2020 Nine Months Ended September 30, 2021 2020 Supplemental disclosures of non-cash investing and financing activities: Cash paid during the period for interest $ 13 $ 12 Issuance of common stock upon vesting of restricted stock units (Note 6) $ 14 $ 16 Issuance of common stock to Juvenescence (Note 5) $ - $ 37 Issuance of warrants to Juvenescence (Note 5) $ 757 $ 1,351

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Lease Agreement On April 2, 2019, the term of a sublease that AgeX entered into during March 2019 (the “AgeX Lease”) went into effect for an office and research facility (the “Alameda Facility”) comprising approximately 23,911 35,866.50 36,942.50 December 31, 2020 In connection with the AgeX Lease, as of December 31, 2019, AgeX incurred $ 436,000 Subleases During 2019, AgeX, as a sublessor, entered into sublease agreements (the “AgeX Subleases”) with unrelated parties (the “Sublessees”) to lease approximately 11,121 3,088.50 15,405.40 16,311.60 December 31, 2020 Office Lease Agreement Effective January 1, 2021, AgeX relocated its principal offices to 1101 Marina Village Parkway, Suite 201, Alameda, California following the December 31, 2020 expiration of the AgeX Lease. AgeX’s new office occupies 135 947 January 1, 2022 1,074 ASC 842 AgeX adopted ASC 842 in 2019. AgeX recorded a right-of-use asset of $ 726,000 There were no future minimum lease commitments as of September 30, 2021. Litigation – General AgeX is subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When AgeX is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, AgeX will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, AgeX discloses the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. AgeX is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations. Employment Contracts AgeX has entered into employment contracts with certain executive officers. Under the provisions of the contracts, AgeX may be required to incur severance obligations for matters relating to changes in control, as defined, and involuntary terminations. Indemnification In the normal course of business, AgeX may provide indemnifications of varying scope under AgeX’s agreements with other companies or consultants, typically for AgeX’s pre-clinical programs. Pursuant to these agreements, AgeX will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with AgeX’s pre-clinical programs. Indemnification provisions could also cover third-party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to AgeX’s pre-clinical programs. Office and laboratory leases will also generally indemnify the lessor with respect to certain matters that may arise during the term of the lease. The sales agreement between AgeX and Chardan also includes indemnification provisions pursuant to which the parties have agreed to indemnify each other from certain liabilities that could arise from the offer and sale of AgeX common stock through the ATM facility, including liabilities under the Securities Act. Similarly, the Registration Rights Agreements between Juvenescence and AgeX include indemnification provisions pursuant to which the parties will indemnify each other from certain liabilities in connection with the registration, offer, and sale of securities under a registration statement, including liabilities arising under the Securities Act. The term of these indemnification obligations will generally continue in effect after the termination or expiration of the particular research, development, services, license, or lease agreement to which they relate. The potential future payments AgeX could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, AgeX has not been subject to any claims or demands for indemnification. AgeX also maintains various liability insurance policies that limit AgeX’s financial exposure. As a result, AgeX believes the fair value of these indemnification agreements is minimal. Accordingly, AgeX has not recorded any liabilities for these agreements to date. Paycheck Protection Program Loan On April 13, 2020, AgeX obtained a loan in the amount of $ 432,952 1 April 13, 2022 On December 27, 2020, the Consolidated Appropriations Act of 2021 was signed into law, retroactively allowing a federal deduction of the expenses that gave rise to the PPP loan forgiveness. California does not allow a deduction for these expenses for publicly traded companies. Notice of Delisting On June 1, 2020, AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders’ equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the “Compliance Plan”) advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. The Exchange staff accepted the Compliance Plan. On April 15, 2021, AgeX regained compliance with all of the Exchange’s continued listing standards set forth in Part 10 of the Exchange Company Guide. Specially, the Exchange has resolved the continued listing deficiency with respect to Section 1003(a)(i) of the Exchange Company Guide. However, as a result of the subsequent decline in the market price of AgeX common stock, the total value of market capitalization or “market cap” of AgeX common stock fell below the $ 50 million level that provided an exemption from meeting the stockholder’s equity requirement of the Exchange’s continued listing standards. The Exchange staff will continue to monitor AgeX’s market cap over the next few months and may take action, including truncating the compliance procedures described in Section 1009 of the Exchange Company Guide or immediately initiating delisting proceedings if we do not regain compliance. AgeX intends to make arrangements to have its common stock quoted on an interdealer quotation system if its common stock is delisted from the Exchange.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events Additional Draws under the 2019 Loan Agreement as Amended in February 2021 On October 25, 2021, AgeX borrowed an additional $ 500,000 under the 2019 Loan Agreement. The outstanding principal balance of the loans totaling $ 6.0 million plus the $ 160,000 Origination Fee under the 2019 Loan Agreement will become due and payable on the Extended Repayment Date on February 14, 2022 . Second Amendment to 2019 Loan Agreement On November 8, 2021, AgeX and Juvenescence entered into Amendment No. 2 to Loan Facility Agreement (the “Second Amendment”) further amending the 2019 Loan Agreement. The Second Amendment increases the amount of the loan facility from $ 6.0 million to $ 7.0 million, of which AgeX previously borrowed $ 6.0 million. All loans in excess of the amount previously borrowed are subject to Juvenescence’s discretion. Additional loans, if made, will be in denominations of $ 1.0 million.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation AgeX’s condensed consolidated interim financial statements include the accounts of its subsidiaries and certain research and development departments. AgeX consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because AgeX has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of stockholders’ deficit on AgeX’s condensed consolidated balance sheets. AgeX’s consolidated balance sheet at December 31, 2020, as reported, includes LifeMap Sciences’ consolidated assets and liabilities, after intercompany eliminations. However, LifeMap Sciences’ consolidated assets and liabilities are not included in AgeX’s unaudited condensed consolidated balance sheet at September 30, 2021, due to the deconsolidation of LifeMap Sciences on March 15, 2021. LifeMap Sciences’ consolidated financial statements and consolidated results of operations include its wholly-owned and consolidated subsidiary LifeMap Sciences, Ltd. AgeX’s unaudited condensed consolidated statements of operations for the nine months ended September 30, 2021 include LifeMap Sciences’ consolidated results for the period through March 15, 2021 rather than the day immediately preceding the deconsolidation due to the conversion of $ 1,761,296 AgeX has one operating subsidiary, ReCyte Therapeutics, Inc. (“ReCyte”). ReCyte is an early stage pre-clinical research and development company involved in stem cell-derived endothelial and cardiovascular related progenitor cells for the treatment of vascular disorders and ischemic conditions. AgeX owns 94.8
Revenue recognition	Revenue recognition During the first quarter of 2018, AgeX adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASU 2014-09, Revenues from Contracts with Customers (Topic 606) AgeX recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it expects to receive in exchange for such product or service. In doing so, AgeX follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. AgeX considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. AgeX applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. Subscription and advertisement revenues ® ® LifeMap Sciences licensed from third parties the databases and software it commercialized and had a contractual obligation to pay royalties to the licensor on subscriptions sold. These costs were included in operating loss from discontinued operations on the condensed consolidated statements of operations when the cash was received and the royalty obligation was incurred as the royalty payments did not qualify for capitalization of costs to fulfill a contract under ASC 340-40, Other Assets and Deferred Costs - Contracts with Customers For the three and nine months ended September 30, 2020, LifeMap Sciences recognized $ 309,000 945,000 267,000 No Grant revenues – AgeX believes the recognition of revenue as costs are incurred and amounts become realizable is analogous to the concept of transfer of control of a service over time under ASC 606. In September 2018, AgeX was awarded a grant of up to approximately $ 225,000 nil 25,000 On April 8, 2020, AgeX was awarded a grant of up to approximately $ 386,000 22,000 40,000 79,000 137,000 Arrangements with multiple performance obligations –
Research and development	Research and development Research and development expenses consist primarily of personnel costs and related benefits, including stock-based compensation, amortization of intangible assets, outside consultants and suppliers, and license fees paid to third parties to acquire patents or licenses to use patents and other technology. Research and development expenses incurred and reimbursed by grants from third parties or governmental agencies, including service revenues from co-development projects with customers, if any and as applicable, approximate the respective revenues recognized in the condensed consolidated statements of operations.
General and administrative	General and administrative General and administrative expenses consist primarily of compensation and related benefits, including stock-based compensation, for executive and corporate personnel, and professional and consulting fees.
Basic and diluted net loss per share attributable to common stockholders	Basic and diluted net loss per share attributable to common stockholders Basic loss per share is calculated by dividing net loss attributable to AgeX common stockholders by the weighted average number of shares of common stock outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by AgeX, if any, during the period. Diluted loss per share is calculated by dividing the net income attributable to AgeX common stockholders, if any, by the weighted average number of shares of common stock outstanding, adjusted for the effects of potentially dilutive common stock issuable under outstanding stock options, warrants, and restricted stock units, using the treasury-stock method, and convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any. For the three and nine months ended September 30, 2021 and 2020, because AgeX reported a net loss attributable to common stockholders, all potentially dilutive common stock, comprised of stock options, restricted stock units and warrants, is antidilutive. The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (unaudited and in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Stock options 3,381 2,892 3,066 2,882 Warrants (1) 3,512 2,036 3,485 1,029 Restricted stock units 21 34 24 39 (1) As of September 30, 2021 and 2020, AgeX had issued Juvenescence warrants to purchase 3,512,098 2,638,401
Leases	Leases On January 1, 2019, AgeX adopted ASU 2016-02, Leases Codification Improvements to Topic 842, Leases Leases (Topic 842): Targeted Improvements AgeX management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a financing lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, AgeX continues to use (i) 75% or greater to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) 90% or greater to determine whether the present value of the sum of lease payments is substantially all of the fair value of the underlying asset. Under the available practical expedients, and as applicable, AgeX accounts for the lease and non-lease components as a single lease component. AgeX recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the consolidated balance sheet. ROU assets represent an entity’s right to use an underlying asset during the lease term and lease liabilities represent an entity’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. If the lease agreement does not provide an implicit rate in the contract, an entity uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the entity will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Upon adoption of ASC 842 and based on the practical expedients available under that standard, AgeX did not reassess any expired or existing contracts, reassess the lease classification for any expired or existing leases and reassess initial direct costs for exiting leases. AgeX also elected not to capitalize leases that have terms of twelve months or less. AgeX’s sublease of its office and laboratory facility, which commenced on April 2, 2019 and ended on December 31, 2020, was subject to ASC 842. AgeX recognized its lease as a right-of-use asset included in property and equipment, net and operating lease liability on its balance sheet in accordance with ASC 842 up until the lease terminated on December 31, 2020 (see Note 10). During 2020, AgeX as a sublessor subleased portions of its office and laboratory space to certain unaffiliated third parties. These subleases are not accounted for under ASC 842 as amounts are not material and or the sublease periods are under one year. On November 3, 2020, AgeX entered into a one year lease effective January 1, 2021 for office space only comprising 135 square feet in a building in an office and research park at 1101 Marina Village Parkway, Suite 201, Alameda, California. Base monthly rent is $947 over the lease term. AgeX has elected to not apply the recognition requirements under ASC 842 and instead recognizes the lease payments as lease cost on a straight-line basis over the lease term as lease payments are not deemed material. AgeX has renewed this lease for another 12 months effective January 1, 2022 for base monthly rent of $1,074. AgeX has elected to not apply the recognition requirements under ASC 842 for the renewed lease agreement under the guidance for similar reasons aforementioned.
Restricted Cash	Restricted Cash In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash Schedule of Cash, Cash Equivalents and Restricted Cash 2021 2020 2020 2019 September 30, December 31, September 30, December 31, 2021 2020 2020 2019 (unaudited) (unaudited) Cash and cash equivalents $ 731 $ 527 $ 1,107 $ 2,352 Restricted cash included in deposits and other long-term assets 50 50 100 100 Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows $ 781 $ 577 $ 1,207 $ 2,452 Restricted cash entirely represents the deposit required to maintain AgeX’s corporate credit card program. All restricted cash was included in deposits and other long-term assets in the condensed consolidated balance sheets.
Reclassifications	Reclassifications Certain reclassifications have been made to the prior years’ consolidated financial statements to conform to current year presentation of discontinued operations. Certain financial information is presented on a rounded basis, which may cause minor differences. See Note 3 for further information on discontinued operations.
Recently adopted accounting pronouncement	Recently adopted accounting pronouncement In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)
Recently issued accounting pronouncements not yet adopted	Recently issued accounting pronouncements not yet adopted The recently issued accounting pronouncements applicable to AgeX that are not yet effective should be read in conjunction with the recently issued accounting pronouncements, as applicable and disclosed in AgeX’s Annual Report on Form 10-K for the year ended December 31, 2020. In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)
CARES Act	CARES Act On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (“CARES”) Act was enacted and signed into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. AgeX reviewed the provisions of the CARES Act but does not expect it to have a material impact to its tax provision or its condensed consolidated financial statements. As described in Note 10, AgeX has obtained a loan under the Paycheck Protection Program under the CARES Act, the repayment of which was forgiven in February 2021.

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following weighted average common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive (unaudited and in thousands): Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Stock options 3,381 2,892 3,066 2,882 Warrants (1) 3,512 2,036 3,485 1,029 Restricted stock units 21 34 24 39 (1) As of September 30, 2021 and 2020, AgeX had issued Juvenescence warrants to purchase 3,512,098 2,638,401
Schedule of Cash, Cash Equivalents and Restricted Cash	In accordance with ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash Schedule of Cash, Cash Equivalents and Restricted Cash 2021 2020 2020 2019 September 30, December 31, September 30, December 31, 2021 2020 2020 2019 (unaudited) (unaudited) Cash and cash equivalents $ 731 $ 527 $ 1,107 $ 2,352 Restricted cash included in deposits and other long-term assets 50 50 100 100 Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows $ 781 $ 577 $ 1,207 $ 2,452

Disposition and Deconsolidati_2

Disposition and Deconsolidation of LifeMap Sciences (Tables)	9 Months Ended
	Sep. 30, 2021
Insurance [Abstract]
Schedule of Discontinued Operations	The following table presents the major classes of assets and liabilities of LifeMap Sciences included in AgeX’s condensed consolidated balance sheet as of December 31, 2020 (in thousands). Schedule of Discontinued Operations December 31, 2020 Cash and cash equivalents $ 391 Accounts and grants receivable, net 173 Prepaid expenses and other current assets 7 Total current assets 571 Intangible assets, net 591 Accounts payable and accrued liabilities 161 Deferred revenues 275 Insurance premium and other current liabilities 1,995 Total current liabilities 2,431 Deferred revenues, net of current portion 64 Net liabilities of discontinued operations $ (1,333 ) The results of operations and cash flows for LifeMap Sciences are reported as discontinued operations under GAAP in accordance with ASC 205-20, Discontinued Operations 2021 2020 2021 2020 Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net revenues $ - $ 365 $ 277 $ 1,160 Costs, operating and other expenses - (406 ) (380 ) (1,689 ) Loss from discontinued operations - (41 ) (103 ) (529 ) Net loss from discontinued operations attributable to noncontrolling interest - 20 7 96 Loss from discontinued operations (1) $ - $ (21 ) $ (96 ) $ (433 ) (1) Does not include $ 106,000 Gain on deconsolidation of LifeMap Sciences

Selected Balance Sheet Compon_2

Selected Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Intangible Assets, Net	At September 30, 2021 and December 31, 2020, intangible assets, primarily consisting of acquired in-process research and development and patents, and accumulated amortization were as follows (in thousands): Schedule of Intangible Assets, Net September 30, 2021 (unaudited) (1) December 31, 2020 Intangible assets $ 1,312 $ 5,586 Accumulated amortization (410 ) (3,994 ) Total intangible assets, net $ 902 $ 1,592 (1) Reflects the effect of the LifeMap Deconsolidation. See Note 3.
Schedule of Accounts Payable and Accrued Liabilities	At September 30, 2021 and December 31, 2020, accounts payable and accrued liabilities were comprised of the following (in thousands): Schedule of Accounts Payable and Accrued Liabilities September 30, 2021 (unaudited) (1) December 31, 2020 Accounts payable $ 184 (1) $ 761 Accrued compensation 201 (1) 228 Accrued vendors and other expenses 539 (1) 667 Total accounts payable and accrued liabilities $ 924 (1) $ 1,656 (1) Reflects the effect of the LifeMap Deconsolidation. See Note 3.

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Summary of Reconciliation Changes in Stockholders’ Equity	The following tables provide the activity in stockholders’ equity (deficit) for the three and nine months ended September 30, 2021 and 2020 (unaudited and in thousands): Summary of Reconciliation Changes in Stockholders’ Equity Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income Equity (Deficit) Common Stock Additional Accumulated Other Total Stockholders’ Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income Equity (Deficit) BALANCE AT JUNE 30, 2021 37,937 $ 4 $ 93,379 $ (101,635 ) $ (42 ) $ - $ (8,294 ) Issuance of common stock Issuance of common stock, shares Issuance of warrants Transactions with noncontrolling interests – LifeMap Sciences Deconsolidation of LifeMap Sciences Foreign currency translation adjustment Issuance of common stock to Juvenescence Issuance of common stock to juvenescence , shares Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 2 - (1 ) - - - (1 ) Stock-based compensation - - 272 - - - 272 Net loss - - - (1,955 ) - - (1,955 ) BALANCE AT SEPTEMBER 30, 2021 37,939 $ 4 $ 93,650 $ (103,590 ) $ (42 ) $ - $ (9,978 ) Common Stock Additional Accumulated Other Total Stockholders’ Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income Equity (Deficit) BALANCE AT DECEMBER 31, 2020 37,691 $ 4 $ 91,810 $ (97,073 ) $ (280 ) $ 143 $ (5,396 ) Issuance of common stock 242 - 475 - - - 475 Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 6 - (6 ) - - - (6 ) Issuance of warrants - - 757 - - - 757 Stock-based compensation - - 740 - - - 740 Transactions with noncontrolling interests – LifeMap Sciences - - (269 ) - 269 - - Deconsolidation of LifeMap Sciences - - 143 - (22 ) (143 ) (22 ) Net loss - - - (6,517 ) (9 ) - (6,526 ) BALANCE AT SEPTEMBER 30, 2021 37,939 $ 4 $ 93,650 $ (103,590 ) $ (42 ) $ - $ (9,978 ) Common Stock Additional Accumulated Other Total Stockholders’ Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income Equity (Deficit) BALANCE AT JUNE 30, 2020 37,658 $ 4 $ 89,555 $ (92,084 ) $ 322 $ 81 $ (2,122 ) Issuance of common stock to Juvenescence 29 - 37 - - - 37 Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 2 - (1 ) - - - (1 ) Issuance of warrants to Juvenescence - - 662 - - - 662 Stock-based compensation - - 232 - - - 232 Transactions with noncontrolling interests – LifeMap Sciences - - 395 - (395 ) - - Foreign currency translation adjustment - - - - - 11 11 Net loss - - - (2,543 ) (22 ) - (2,565 ) BALANCE AT SEPTEMBER 30, 2020 37,689 $ 4 $ 90,880 $ (94,627 ) $ (95 ) $ 92 $ (3,746 ) Common Stock Additional Accumulated Other Total Stockholders’ Number of Shares Par Value Paid-In Capital Accumulated Deficit Noncontrolling Interest Comprehensive Income Equity (Deficit) BALANCE AT DECEMBER 31, 2019 37,649 $ 4 $ 88,353 $ (86,208 ) $ 399 $ 69 $ 2,617 Balance 37,649 $ 4 $ 88,353 $ (86,208 ) $ 399 $ 69 $ 2,617 Issuance of common stock to Juvenescence 29 - 37 - - - 37 Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes 11 - (7 ) - - - (7 ) Issuance of warrants to Juvenescence - - 1,351 - - - 1,351 Stock-based compensation - - 751 - - - 751 Transactions with noncontrolling interests – LifeMap Sciences - - 395 - (395 ) - - Foreign currency translation adjustment - - - - - 23 23 Net loss - - - (8,419 ) (99 ) - (8,518 ) BALANCE AT SEPTEMBER 30, 2020 37,689 $ 4 $ 90,880 $ (94,627 ) $ (95 ) $ 92 $ (3,746 ) Balance 37,689 $ 4 $ 90,880 $ (94,627 ) $ (95 ) $ 92 $ (3,746 )

Stock-Based Awards (Tables)

Stock-Based Awards (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Summary of Stock Option Activity	A summary of AgeX stock option activity under the Plan and related information follows (in thousands, except weighted average exercise price): Summary of Stock Option Activity Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price December 31, 2020 1,046 2,854 28 $ 2.51 Options granted (568 ) 568 - 1.46 Options forfeited, cancelled or expired 40 (40 ) - 3.00 Restricted stock units vested - - (9 ) - September 30, 2021 518 3,382 19 $ 2.31 Options exercisable at September 30, 2021 2,398 $ 2.50
Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options	The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions including expected life, risk-free interest rates, volatility, and dividend yield. No stock options were granted under the Plan during the three months ended September 30, 2021 and 2020. Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options Nine Months Ended September 30, 2021 2020 Expected life (in years) 5.71 6.08 Risk-free interest rates 0.99 % 0.45 % Volatility 102.34 % 87.86 % Dividend yield - % - %
Schedule of Stock Based Compensation Expense	Operating expenses include stock-based compensation expense as follows (unaudited and in thousands): Schedule of Stock Based Compensation Expense Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 17 $ 16 $ 48 $ 63 General and administrative 255 211 688 669 Total stock-based compensation expense – continued operations $ 272 $ 227 $ 736 $ 732

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Schedule Non-cash Investing and Financing Transactions	Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the nine months ended September 30, 2021 and 2020 are as follows (unaudited and in thousands): Schedule Non-cash Investing and Financing Transactions 2021 2020 Nine Months Ended September 30, 2021 2020 Supplemental disclosures of non-cash investing and financing activities: Cash paid during the period for interest $ 13 $ 12 Issuance of common stock upon vesting of restricted stock units (Note 6) $ 14 $ 16 Issuance of common stock to Juvenescence (Note 5) $ - $ 37 Issuance of warrants to Juvenescence (Note 5) $ 757 $ 1,351

Organization, Business Overvi_2

Organization, Business Overview and Liquidity (Details Narrative)	Mar. 15, 2021USD ($)	Apr. 30, 2020USD ($)Integer	Nov. 08, 2021USD ($)	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2019USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accumulated deficit				$ 103,590,000	$ 97,073,000
Cash and Cash Equivalents, at Carrying Value				731,000	$ 527,000	$ 1,107,000	$ 2,352,000
Number of staff layoffs | Integer		11
Accrued payroll		$ 105,000
Restructuring charges		$ 195,000
Merger Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of merger consideration on pro rata portion	$ 466,400
Debt converted to equity	1,761,296
Paid in cash portion of indebtedness	250,000
LIfe Map Sciences Inc [Member] | Merger Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Payment of merger consideration on pro rata portion	$ 500,000
Juvenescence Limited [Member] | Loan Facility Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity				$ 1,000,000
Juvenescence Limited [Member] | Second Amendment to 2019 Loan Agreement [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 1,000,000

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares shares in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		3,381	2,892	3,066	2,882
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	[1]	3,512	2,036	3,485	1,029
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		21	34	24	39
[1]	As of September 30, 2021 and 2020, AgeX had issued Juvenescence warrants to purchase 3,512,098 2,638,401

Schedule of Antidilutive Secu_2

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) (Parenthetical) - shares	Sep. 30, 2021	Sep. 30, 2020
Juvenescence Limited [Member] | Loan Agreement [Member]
Warrants to purchase common stock	3,512,098	2,638,401

Schedule of Cash, Cash Equivale

Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 731	$ 527	$ 1,107	$ 2,352
Restricted cash included in deposits and other long-term assets	50	50	100	100
Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows	$ 781	$ 577	$ 1,207	$ 2,452

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Mar. 15, 2021	Apr. 08, 2018	Sep. 30, 2018	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Product Information [Line Items]
Revenues				$ 24,000	$ 69,000	$ 117,000	$ 203,000
Grant Revenues [Member]
Product Information [Line Items]
Revenues		$ 386,000		22,000	40,000	79,000	162,000
LifeMap Sciences [Member] | Subscription and Advertising Revenues [Member]
Product Information [Line Items]
Revenues				0	309,000,000	267,000,000	945,000,000
National Institutes of Health [Member] | For Treating Osteoporosis [Member]
Product Information [Line Items]
Allowable expenses of grant revenues							25,000
National Institutes of Health [Member] | For Treating Stroke [Member]
Product Information [Line Items]
Allowable expenses of grant revenues				$ 22,000	$ 40,000	79,000	$ 137,000
National Institutes of Health [Member] | Grant Revenues [Member]
Product Information [Line Items]
Revenues			$ 225,000
Merger Agreement [Member]
Product Information [Line Items]
Indebtedness cash	$ 1,761,296					$ 1,761,296
Merger Agreement [Member] | ReCyte Therapeutics, Inc. [Member]
Product Information [Line Items]
Ownership interest	94.80%

Schedule of Discontinued Operat

Schedule of Discontinued Operations (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Schedule of Equity Method Investments [Line Items]
Net revenues		$ 24	$ 69	$ 117	$ 203
Loss from discontinued operations			(41)	(103)	(529)
Net loss from discontinued operations attributable to noncontrolling interest			(20)	(7)	(96)
LifeMap Sciences [Member]
Schedule of Equity Method Investments [Line Items]
Cash and cash equivalents						$ 391
Accounts and grants receivable, net						173
Prepaid expenses and other current assets						7
Total current assets						571
Intangible assets, net						591
Accounts payable and accrued liabilities						161
Deferred revenues						275
Insurance premium and other current liabilities						1,995
Total current liabilities						2,431
Deferred revenues, net of current portion						64
Net liabilities of discontinued operations						$ (1,333)
Net revenues			365	277	1,160
Costs, operating and other expenses			(406)	(380)	(1,689)
Loss from discontinued operations			(41)	(103)	(529)
Net loss from discontinued operations attributable to noncontrolling interest			20	7	96
Loss from discontinued operations	[1]		$ (21)	$ (96)	$ (433)
[1]	Does not include $ 106,000 Gain on deconsolidation of LifeMap Sciences

Schedule of Discontinued Oper_2

Schedule of Discontinued Operations (Details) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Deconsolidation, gain (loss), amount			$ 106,000
Discontinued Operations [Member]
Deconsolidation, gain (loss), amount			$ 106,000

Disposition and Deconsolidati_3

Disposition and Deconsolidation of LifeMap Sciences (Details Narrative) - USD ($)	Mar. 15, 2021	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Gain on deconsolidation of LifeMap Sciences				$ 106,000
Merger Agreement [Member]
Payment of merger consideration on pro rata portion	$ 466,400
Debt converted to equity	1,761,296
Paid in cash portion of indebtedness	250,000
Indebtedness cash	1,761,296			$ 1,761,296
LIfe Map Sciences Inc [Member] | Merger Agreement [Member]
Payment of merger consideration on pro rata portion	$ 500,000

Schedule of Intangible Assets,

Schedule of Intangible Assets, Net (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Intangible assets	$ 1,312	$ 5,586
Accumulated amortization	(410)	(3,994)
Total intangible assets, net	$ 902	$ 1,592

Schedule of Accounts Payable an

Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	[1]	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts payable	$ 184		$ 761
Accrued compensation	201		228
Accrued vendors and other expenses	539		667
Total accounts payable and accrued liabilities	$ 924		$ 1,656
[1]	Reflects the effect of the LifeMap Deconsolidation. See Note 3.

Selected Balance Sheet Compon_3

Selected Balance Sheet Components (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Depreciation	$ 381,000		$ 381,000		$ 381,000
Depreciation and amortization expense		$ 230,000		$ 686,000
Amortization of intangible assets		33,000	98,000	98,000
Discontinued Operations [Member]
Property, Plant and Equipment [Line Items]
Amortization of intangible assets		$ 107,000	89,000	$ 321,000
Research and Development [Member]
Property, Plant and Equipment [Line Items]
Amortization of intangible assets	$ 32,000		$ 98,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Feb. 10, 2021	Mar. 30, 2020	Oct. 13, 2019	Aug. 13, 2019	Oct. 31, 2018	Sep. 30, 2021
Value of common stock shares issued						$ 475,000
Warrants exercise price, minimum						$ 0.70
Warrants exercise price, maximum						$ 1.895
Common stock held						$ 3,248,246
Chief Operating Officer [Member]
Transactions fixed annual amount					$ 280,000
Related party payables						$ 71,000
Warrant [Member]
Number of common stock shares issued						28,500
Sale of warrants purchase of common stock						3,362,098
Juvenescence's Discretion [Member]
Common stock held						$ 16,447,500
2020 Loan Agreement [Member]
Line of credit, term		18 months
Line of credit, maximum borrowing capacity		$ 8,000,000				8,000,000
Stock issued during period, shares		28,500
Borrowed an aggregate amount		$ 3,000,000
Line of credit, expiration date		Mar. 30, 2023
Line of credit facility current withdrawings						7,500,000
2020 Loan Agreement [Member] | Juvenescence's Discretion [Member]
Line of credit, maximum borrowing capacity		$ 1,000,000
Line of credit borrowed money in excess		$ 500,000
Juvenescence [Member] | 2019 Loan Agreement [Member]
Related party transaction description			Under those limits (a) the number of shares of common stock that may be issued upon conversion of any loan advance, at a conversion price that is lower than the market price of AgeX common stock at the time of funding the applicable advance being converted, may not exceed 19.9% of the shares outstanding at August 13, 2019, and (b) no advances may be converted into common stock in an amount that would cause Juvenescence’s ownership of AgeX common stock to equal or exceed 50% of the number of shares of AgeX common stock then outstanding.	On August 13, 2019, AgeX and Juvenescence entered into a Loan Facility Agreement (the “2019 Loan Agreement”) pursuant to which Juvenescence has provided to AgeX a $2.0 million line of credit for a period of 18 months. On February 10, 2021, AgeX entered into an amendment (the “Amendment”) to the 2019 Loan Agreement. The Amendment extended the maturity date of loans under the 2019 Loan Agreement to February 14, 2022 (the “Extended Repayment Date”) and increased the amount of the loan facility by $4.0 million. All loans in excess of the initial $2.0 million under the 2019 Loan Agreement that AgeX previously borrowed are subject to Juvenescence’s discretion. As of September 30, 2021 AgeX had borrowed $5.5 million of the $6.0 million total line of credit under the 2019 Loan Agreement, as amended.
Line of credit facility				$ 2,000,000
Line of credit, term				18 months
Increase in line of credit	$ 4,000,000
Line of credit borrowed money in excess not paid	$ 2,000,000			$ 25,000		5,500,000
Line of credit, maximum borrowing capacity						$ 6,000,000
Number of common stock shares issued				19,000
Value of common stock shares issued				$ 56,000
Related Party Transaction, Rate				10.00%
Gross proceeds from sale of common stock				$ 7,500,000
Line of credit borrowed money in excess				$ 100,000
Sale of warrants purchase of common stock				150,000
Warrants exercise price				$ 2.60
Warrants, value				$ 236,000
Origination Fee				$ 160,000

Summary of Reconciliation Chang

Summary of Reconciliation Changes in Stockholders’ Equity (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ (8,294)	$ (2,122)	$ (5,396)	$ 2,617
Issuance of common stock			475
Issuance of warrants to Juvenescence		662	757	1,351
Transactions with noncontrolling interests – LifeMap Sciences
Deconsolidation of LifeMap Sciences			(22)
Foreign currency translation adjustment		11		23
Issuance of common stock to Juvenescence		$ 37		$ 37
Issuance of common stock to juvenescence , shares		29		29
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes	(1)	$ (1)	(6)	$ (7)
Stock-based compensation	272	232	740	751
Net loss	(1,955)	(2,565)	(6,526)	(8,518)
Balance	(9,978)	(3,746)	(9,978)	(3,746)
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 4	$ 4	$ 4	$ 4
Balance, shares	37,937	37,658	37,691	37,649
Issuance of common stock
Issuance of common stock, shares			242
Issuance of warrants to Juvenescence
Transactions with noncontrolling interests – LifeMap Sciences
Deconsolidation of LifeMap Sciences
Foreign currency translation adjustment
Issuance of common stock to Juvenescence
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee's taxes, shares	2	2	6	11
Stock-based compensation
Net loss
Balance	$ 4	$ 4	$ 4	$ 4
Balance, shares	37,939	37,689	37,939	37,689
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ 93,379	$ 89,555	$ 91,810	$ 88,353
Issuance of common stock			475
Issuance of warrants to Juvenescence		662	757	1,351
Transactions with noncontrolling interests – LifeMap Sciences		395	(269)	395
Deconsolidation of LifeMap Sciences			143
Foreign currency translation adjustment
Issuance of common stock to Juvenescence		37		37
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes	(1)	(1)	(6)	(7)
Stock-based compensation	272	232	740	751
Net loss
Balance	93,650	90,880	93,650	90,880
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(101,635)	(92,084)	(97,073)	(86,208)
Issuance of common stock
Issuance of warrants to Juvenescence
Transactions with noncontrolling interests – LifeMap Sciences
Deconsolidation of LifeMap Sciences
Foreign currency translation adjustment
Issuance of common stock to Juvenescence
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes
Stock-based compensation
Net loss	(1,955)	(2,543)	(6,517)	(8,419)
Balance	(103,590)	(94,627)	(103,590)	(94,627)
Noncontrolling Interest [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(42)	322	(280)	399
Issuance of common stock
Issuance of warrants to Juvenescence
Transactions with noncontrolling interests – LifeMap Sciences		(395)	269	(395)
Deconsolidation of LifeMap Sciences			(22)
Foreign currency translation adjustment
Issuance of common stock to Juvenescence
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes
Stock-based compensation
Net loss		(22)	(9)	(99)
Balance	(42)	(95)	(42)	(95)
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance		81	143	69
Issuance of common stock
Issuance of warrants to Juvenescence
Transactions with noncontrolling interests – LifeMap Sciences
Deconsolidation of LifeMap Sciences			(143)
Foreign currency translation adjustment		11		23
Issuance of common stock to Juvenescence
Issuance of common stock upon vesting of restricted stock units, net of shares retired to pay employee’s taxes
Stock-based compensation
Net loss
Balance		$ 92		$ 92

Stockholders_ Equity (Deficit_2

Stockholders’ Equity (Deficit) (Details Narrative) - USD ($)	Jan. 08, 2021	Aug. 13, 2019	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Preferred stock, shares authorized			5,000,000		5,000,000
Preferred Stock, Par or Stated Value Per Share			$ 0.0001		$ 0.0001
Preferred Stock, Shares Outstanding			0		0
Preferred Stock, Shares Issued			0		0
Common stock, shares authorized			100,000,000		100,000,000
Common stock, par value			$ 0.0001		$ 0.0001
Common stock, shares issued			37,939,176		37,691,047
Common stock, shares outstanding			37,939,176		37,691,047
Aggregate offering price of common stock			$ 475,000
Proceeds from sale of common stock			496,000
Juvenescence [Member] | 2019 Loan Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Sale of warrants purchase of common stock		150,000
Number of common stock shares issued		19,000
Aggregate offering price of common stock		$ 56,000
Chardan Capital Markets LLC [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, par value	$ 0.0001
Aggregate offering price of common stock	$ 12,600,000
Proceeds from sale of common stock			496,000
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from loans			$ 7,500,000
Sale of warrants purchase of common stock			3,362,098
Number of common stock shares issued			28,500

Summary of Stock Option Activit

Summary of Stock Option Activity (Details) - Equity Incentive Plan [Member] - Employee Stock [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant, Beginning balance	1,046
Number of Options Outstanding, Beginning balance	2,854
Number of RSUs Outstanding, Beginning balance	28
Weighted Average Exercise Price, Outstanding, Beginning balance | $ / shares	$ 2.51
Shares Available for Grant, Options granted	(568)
Number of Options Outstanding, Options granted	568
Number of RSUs Outstanding, Options granted
Weighted Average Exercise Price, Options granted | $ / shares	$ 1.46
Shares Available for Grant, Options forfeited, cancelled or expired	40
Number of Options Outstanding, Options forfeited, cancelled or expired	(40)
Number of RSUs Outstanding, Options forfeited, cancelled or expired
Weighted Average Exercise Price, Options forfeited, cancelled or expired | $ / shares	$ 3
Shares Available for Grant, Restricted stock units vested
Number of Options Outstanding, Restricted stock units vested
Number of RSUs Outstanding, Restricted stock units vested	(9)
Weighted Average Exercise Price, Restricted stock units vested | $ / shares
Shares Available for Grant, Ending balance	518
Number of Options Outstanding, Ending balance	3,382
Number of RSUs Outstanding, Ending balance	19
Weighted Average Exercise Price, Outstanding, Ending balance | $ / shares	$ 2.31
Number of Options Outstanding, Exercisable, Ending balance	2,398
Weighted Average Exercise Price, Exercisable, Ending balance | $ / shares	$ 2.50

Schedule of Weighted Average As

Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Expected life (in years)	5 years 8 months 15 days	6 years 29 days
Risk-free interest rates	0.99%	0.45%
Volatility	102.34%	87.86%
Dividend yield

Schedule of Stock Based Compens

Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 272	$ 227	$ 736	$ 732
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	17	16	48	63
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 255	$ 211	$ 688	$ 669

Stock-Based Awards (Details Nar

Stock-Based Awards (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options exercised		0
Stock-based compensation expense recognized under discontinued operations	$ 5,000	$ 4,000	$ 19,000
2017 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of common stock reserved		4,000,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Operating Loss Carryforwards [Line Items]
Income tax provision	$ 0	$ 0
GILTI [Member]
Operating Loss Carryforwards [Line Items]
Income tax rate deduction		50.00%

Schedule Non-cash Investing and

Schedule Non-cash Investing and Financing Transactions (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Cash paid during the period for interest	$ 13	$ 12
Issuance of common stock upon vesting of restricted stock units (Note 6)	14	16
Issuance of common stock to Juvenescence (Note 5)		37
Issuance of warrants to Juvenescence (Note 5)	$ 757	$ 1,351

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	Jun. 02, 2020	Apr. 13, 2020USD ($)	Apr. 02, 2019USD ($)ft²	Sep. 30, 2021USD ($)ft²	Sep. 30, 2021USD ($)ft²	Dec. 31, 2019USD ($)ft²	Apr. 15, 2021USD ($)
Notice of Delisting	AgeX received a letter (the “Deficiency Letter”) from the staff of the NYSE American (the “Exchange”) indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) of the Exchange Company Guide in that AgeX has stockholders’ equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter AgeX provided the Exchange staff with a plan (the “Compliance Plan”) advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by December 1, 2021. The Exchange staff accepted the Compliance Plan.
[custom:ThresholdMarketCapLimitForExemption-0]							$ 50,000,000
Axos Bank [Member] | Paycheck Protection Program [Member]
Loan obtained		$ 432,952
Interest rate		1.00%
Loan maturity date		Apr. 13, 2022
Accounting Standards Update 2016-02 [Member]
Right-of-use asset						$ 726,000
Right-of-use liability						726,000
Lease Agreement [Member]
Area of land | ft²			23,911	135	135
Base rent			$ 35,866.50		$ 947
Increase in base rent			$ 36,942.50
Lease expiration			Dec. 31, 2020
Tenant improvement expenses						$ 436,000
SubLease Agreement [Member]
Area of land | ft²						11,121
Base rent						$ 16,311.60
Lease expiration						Dec. 31, 2020
SubLease Agreement [Member] | First Sublessee [Member]
Base rent						$ 3,088.50
SubLease Agreement [Member] | Second Sublessee [Member]
Base rent						$ 15,405.40
Extension of Lease Agreement [Member]
Base rent				$ 1,074
Lease extension effective date				Jan. 1, 2022

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Oct. 25, 2021	Nov. 08, 2021
Amendment to 2019 Loan Agreement [Member] | Juvenescence [Member]
Subsequent Event [Line Items]
Loans Payable	$ 500,000
Line of credit facility current withdrawings	6,000,000	$ 6,000,000
Debt Instrument, Fee Amount	$ 160,000
Line of Credit Facility, Expiration Date	Feb. 14, 2022
Second Amendment to 2019 Loan Agreement [Member] | Juvenescence [Member] | Minimum [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		6,000,000
Second Amendment to 2019 Loan Agreement [Member] | Juvenescence [Member] | Maximum [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		7,000,000
Second Amendment to 2019 Loan Agreement [Member] | Juvenescence Limited [Member]
Subsequent Event [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity		$ 1,000,000